Pfizer applied for full approval for Covid vaccine in Brazil
The Pfizer BioNTech vaccine is the second submitted for full approval in Brazil after AstraZeneca applied on January 29 for the vaccine it created with Oxford University.
That vaccine is being manufactured in Brazil in partnership with the federally funded Fiocruz biomedical center.
Brazil has already approved the Oxford-AstraZeneca vaccine and the Chinese-developed SinoVac shots for emergency use and began a vaccination drive in mid-January; but that roll-out has been plagued by delays in ingredient shipments.
The Pfizer-BioNTech vaccine has overall efficacy of 95 percent, and the efficacy of 94 percent in people aged over 65; Pfizer has said. The prospect of distributing a new vaccine in Brazil came as Bolsonaro has faced protests; largely organized by left-wing parties and groups – against his handling of the pandemic.
The president previously dismissed the virus as a “little flu” and rejected the need to put public health restrictions in place to prevent its spread. He also has said he will not receive a vaccine, even as the pandemic continued to rage in the country.
During the past month, more than 1,000 coronavirus-related deaths have been recorded daily. More than 9.4 million infections, as well as more than 230,000 deaths, have been reported to date.
Preliminary investigation opened
The country’s prosecutor-general last week opened a preliminary investigation into Bolsonaro for a deadly coronavirus outbreak in Manaus, the capital of the country’s Amazonas state.
In January, the city’s hospitals ran out of oxygen; forcing the federal government to fly in supplies from across the country.
The region is also where a new coronavirus variant believed to be more easily transmissible; similar to those found in the United Kingdom and South Africa – first appeared.
If the initial inquiry, which also includes Health Minister Eduardo Pazuello; finds “possible wrongdoing”, a more formal investigation known as an “inquiries” will take place to find the facts in depth.
